The design of this study really is a shame. We are still at phase 1 studies, or phase 2 at best for the protocol. That being the case they should test the protocol on cancers for which chemotherapy is known to be effective, as metronomic therapy is intended to make that available to a population of persons who otherwise can not tolerate the negative effects of chemo ... the purpose should not be to cure that which is not curable via standard chemo. It was a study designed to fail by not using the recommended test group. They never make this mistake when testing pharmaceutical company (…)